Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Folate receptor beta (FR-beta), encoded by the FOLR2 gene, is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein that binds folic acid and its reduced derivatives with high affinity. Unlike folate receptor alpha (FR-alpha), which is primarily expressed on epithelial cells, FOLR2 is selectively expressed on cells of the myeloid lineage, particularly activated macrophages, monocytes, and malignant myeloid cells. In the tumor microenvironment, FOLR2 is highly upregulated on immunosuppressive M2-polarized tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), where it contributes to tumor progression, immune evasion, and metastasis. It is also highly expressed on leukemic blasts in acute myeloid leukemia (AML) and on activated macrophages in chronic inflammatory and autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, and myocarditis.
Due to its restricted expression profile, FOLR2 represents an attractive therapeutic target for both direct cancer therapy and macrophage-reprogramming immunotherapies. Therapeutic strategies targeting FOLR2 include monoclonal antibodies (e.g., m909) that induce antibody-dependent cell-mediated cytotoxicity (ADCC), folate-drug conjugates (e.g., the folate-aminopterin conjugate EC2319) that deliver cytotoxic payloads directly to activated macrophages, and CAR-T cell therapies. Additionally, FOLR2 is utilized as a target for non-invasive PET imaging and fluorescence-guided surgery using folate-conjugated tracers and dyes like pafolacianine.
Antibody-dependent cell-mediated cytotoxicity (ADCC), folate-receptor-mediated endocytosis of drug conjugates, and competitive inhibition of folate uptake.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Folate receptor beta (FR-beta) (FOLR2).